A study of HFB200603 as a single agent and in combination with Tislelizumab in patients with advanced solid tumors

2022-502891-22-00 Protocol HFB-200603-01 Human pharmacology (Phase I) - First administration to humans Ended

Start 2 Aug 2023 · End 10 Mar 2026 · Status Ended · 2 EU/EEA countries · 8 sites · Protocol HFB-200603-01

Overview

Sponsor-declared trial summary

Phase Human pharmacology (Phase I) - First administration to humans
Status Ended
Participants planned 135
Countries 2
Sites 8

Advanced Solid Tumors

Key facts

Sponsor
Hifibio Inc.
Participant type
Patients
Age range
18-64 years, 65+ years
Gender
Male and Female
Therapeutic area
Diseases [C] - Neoplasms [C04]
Trial duration
2 Aug 2023 → 10 Mar 2026
Decision date (initial)
2023-07-03
Transition trial
No
Low-intervention
No
Rare-disease indication
No
Vulnerable population
Yes

External identifiers

EU CT number
2022-502891-22-00
WHO UTN
U1111-1285-3903

Trial design

CTIS Part I — objectives, methods, condition coding

Conditions and MedDRA coding

Advanced Solid Tumors

VersionLevelCodeTermSystem organ class
21.1 LLT 10065252 Solid tumor 10029104

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

Hifibio Inc.

Sponsor organisation
Hifibio Inc.
Address
237 Putnam Avenue
City
Cambridge
Postcode
02139-3807
Country
United States

Scientific contact point

Organisation
Hifibio Inc.
Contact name
Regulatory Submissions

Public contact point

Organisation
Hifibio Inc.
Contact name
HiFiBiO Clinical

Locations

2 EU/EEA countries · 8 investigational sites

By country

CountryMS statusPlanned subjectsSites
Italy Ended 39 3
Spain Ended 57 5
Rest of world
United States
39

Investigational sites

Italy

3 sites · Ended
Centro Ricerche Cliniche Di Verona S.r.l.
UOC Oncologia - AOUI Verona, Piazzale Ludovico Antonio Scuro 10, 37134, Verona
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
UOC Fase 1, Largo Francesco Vito 1, 00168, Rome
IRCCS Istituto Nazionale Tumori Fondazione Pascale
S.C. Sperimentazioni Cliniche, Via Mariano Semmola 52, 80131, Naples

Spain

5 sites · Ended
University Clinic Of Navarra
Oncology, Pio XII Etorbidea 36, 31008, Pamplona
Hospital Universitario Hm Sanchinarro
Oncology, Calle Ona 10, 28050, Madrid
Hospital Clinico Universitario De Valencia
Oncology, Avenida Blasco Ibanez 17, 46010, Valencia
University Clinic Of Navarra
Oncology, Calle Marquesado De Santa Marta 1, 28027, Madrid
Hospital Universitario Fundacion Jimenez Diaz
Oncology, Avenida De Los Reyes Catolicos 2, 28040, Madrid

Country notifications

Trial-start, recruitment-start, end and early-termination notifications submitted per Member State

Country Trial startTrial end Recruitment startRecruitment end Early termination
Italy 2023-10-09 2023-11-24 2024-09-24
Spain 2023-08-02 2023-08-11 2024-09-24

Oversight and notifications

Regulatory notifications under CTR Articles 38, 52, 53, 54 and 77

Temporary halts 2 · Art. 38 CTR

Temporary halt TH-107431

Halt date
2025-11-05
Member states concerned
Spain
Publication date
2025-11-20
Reason
Sponsor decision
Benefit-risk balance changed
No
Treatment stopped
No

Temporary halt TH-107430

Halt date
2025-11-05
Member states concerned
Italy
Publication date
2025-11-20
Reason
Sponsor decision
Benefit-risk balance changed
No
Treatment stopped
No

Application history

9 submissions — initial application plus substantial / non-substantial modifications

#TypeCodeSubmittedReference MSConclusionDecision date
1 INITIAL IN 2023-03-21 Spain Acceptable
2023-06-30
2023-07-03
2 SUBSTANTIAL MODIFICATION SM-1 2023-10-18 Spain Acceptable
2023-11-28
2023-11-30
3 NON SUBSTANTIAL MODIFICATION NSM-1 2023-12-20 Spain Acceptable
2023-11-28
2023-12-20
4 SUBSTANTIAL MODIFICATION SM-2 2024-04-18 Spain Acceptable
2024-06-03
2024-06-03
5 NON SUBSTANTIAL MODIFICATION NSM-3 2024-07-19 Spain Acceptable
2024-06-03
2024-07-19
6 NON SUBSTANTIAL MODIFICATION NSM-4 2025-03-05 Spain Acceptable
2024-06-03
2025-03-05
7 SUBSTANTIAL MODIFICATION SM-3 2025-03-20 Spain Acceptable 2025-03-27
8 NON SUBSTANTIAL MODIFICATION NSM-5 2025-07-24 Spain Acceptable 2025-07-24
9 NON SUBSTANTIAL MODIFICATION NSM-6 2025-09-09 Spain Acceptable 2025-09-09